Attema AE.  Developments in time preference and their implications for medical decision making. Journal of the Operational Research Society 2012; 63 (10):1388-1399.

Attema AE, Bleichrodt H, Wakker PP. A direct method for measuring discounting and QALYs more Easily and Reliably. Med Decis Making 2012; (32)4:583-593.

Attema AE, Brouwer WBF. A test of independence of discounting from quality of life. Journal of Health Economics 2012; (31):22-34.

Attema AE, Brouwer WBF. Constantly Proving The Opposite? A test of CPTO using a broad time horizon and correcting for discounting. Qual Life Res 2012; 21:25-34.

Attema AE, Brouwer WBF. The way that you do it? An elaborate test of procedural invariance of TTO, using a choice-based design. The European Journal of Health Economics 2012; 13(4):491-500.

van Baal PH. Important cost categories not included: transcatheter aortic valve implementation probably less cost-effective. Heart 2012; 97:1182.

Bobinac A, van Exel NJA, Rutten FFH, Brouwer WBF. Get more, pay more? An elaborate test of the validity of willingness to pay per QALY estimates obtained through contingent valuation. Journal of Health Economics2012; 31(1): 158-168.

Cleemput I, Franken M, Koopmanschap M, Le Polain M. European drug reimbursement systems’ legitimacy: five-country comparison and policy tool. Int J Technol Assess Health Care 2012; 28(4):358-66.

Franken M, van Gils CW, Gaultney JG, Delwel GO, Goettsch W, Huijgens PC, Steenhoek A, Punt CJ, Koopman M, Redekop WK, Uyl-de Groot CA. Practical feasibility of outcomes research in oncology: Lessons learned in assessing drug use and cost-effectiveness in The Netherlands. Eur J Cancer 2012.

Franken M, Le Polain M, Cleemput I, Koopmanschap M. Similarities and differences between five European drug reimbursement systems. Int J Technol Assess Health Care 2012; 28(4):349-57.

Frederix GWJ, Severens JL, Hövels AM, Raaijmakers JAM, Schellens JHM. Reviewing the Cost-Effectiveness of Endocrine Early Breast Cancer Therapies: Influence of Differences in Modeling Methods on Outcomes.Value in Health 2012:94-105.

Freijer K, Tan SS, Koopmanschap MA, Meijers JM, Halfens RJ, Nuijten MJ. The economic costs of disease related malnutrition. Clinical Nutrition 2012:1-6.

van Gestel A, Grutters J, Schouten J, Webers C, Beckers H, Joore M, Severens J. The Role of the Expected Value of Individualized Care inCost-Effectiveness Analyses and Decision Making. Value in Health 2012:13–21.

van Gestel A, Webers CA, Severens JL, Beckers HJ, Jansonius NM, Hendrikse F, Schouten JS. The long-term outcomes of four alternative treatment strategies for primary open-angle glaucoma. Acta Ophthalmol. 2012;(90):20-31.

Ginsberg GM, Lauer JA, Zelle SG, Baeten SA, Baltussen RMPM. Cost effectiveness of strategies to combat breast, cervical, and colorectal cancer in sub-Saharan Africa and South East Asia: mathematical modelling study. BMJ 2012; 344:1-18.

Goebbels AFG, Lakerveld J, Ament AJHA, Bot SDM, Severens JL. Exploring non-health outcomes of health promotion: The perspective of participants in a lifestyle behaviour change intervention. Health Policy 106 (2012) 177-186.

Hakkaart-van Roijen L, Tan SS. Doelmatigheidsonderzoek in de jeugd-GGZ: Op weg naar volwassenheid.Tijdschrift van de Vereniging voor Kinder- en Jeugdpsychotherapie 2012; 39(1): 39-47.

Handels RLH, Aalten P, Wolfs CAG, OldeRikkert M, Scheltens P, Visser PJ, Joore MA, Severens JL, Verhey FRJ. Diagnostic and economic evaluation of new biomarkers for Alzheimer’s disease: the research protocol of a prospective cohort study. BMC Neurology 2012; 12:72.

van Herk-Sukel MPP, Lemmens VEPP, van de Poll-Franse LV, Herings RMC, Coebergh JWW. Record linkage for pharmacoepidemiological studies in cancer patients. Pharmacoepidemiology and drug safety 2012; (21):94-103.

Hermans J, Koopmanschap MA, Bierma-Zeinstra SM, van Linge JH, Verhaar JA, Reijman M, Burdorf A. Productivity costs and medical costs among working patients with knee osteoarthritis. Arhritis Care Res (Hoboken). 2012; 64(6):853-861.

Hoomans T, Severens JL, van der Roer N, Delwel GO. Methodological Quality of Economic Evaluations of New Pharmaceuticals in the Netherlands. Pharmacoeconomics 2012; 30(3):219-227.

van de Kassteele J, Hoogenveen RT, Engelfriet PM, van Baal PHM, Boshuizen HC. Estimating net transition probabilities from cross-sectional data with application to risk factors in chronic disease modeling. Statistics in Medicine 2012; 31:533–543.

Koopmanschap MA. Generic medicine pricing: on track in Europe? GaBi Journal 2012: 1, 5.

Koopmanschap M, Severens JL, Franken M. Internationale aspecten bij besluitvorming inzake geneesmiddelenvergoeding. ESB dossier Gepaste zorg 2012; Jaargang 97:36-39.

Kraijo H, Brouwer WBF, de Leeuw R, Schrijvers G, van Exel NJA. Coping with caring: Profiles of caregiving by informal carers living with a loved one who has dementia. Dementia 2012;11(1): 113-130

Lhachimi SK, Nusselder WJ, Smit HA, van Baal P, Baili P, Bennett K, Fernandez E, Kulik MC, Lobstein T, Pomerleau J, Mackenbach JP, Boshuizen HC. DYNAMO-HIA-A Dynamic Modeling Tool for Generic Health Impact Assessments. PLoS ONE 7(5).

Majer IM, Mackenbach JP, van Baal PH. Time trends and forecasts of body mass index from repeated cross-sectional data: a different approach. Stat Med. 2012.

Makai P, Brouwer WBF, Koopmanschap MA, Nieboer A. Capabilities and quality of life in Dutch psycho-geriatric nursing homes: An exploratory study using a proxy version of the ICECAP-O. Quality of Life Research 2012; 21(5):801-812.

de Meijer CAM, Majes IM, Koopmanschap MA, van Baal PH. Forecasting lifetime and aggregate long-term care spending. Accounting for changing disability patterns. Med Care 2012; 50:722-729.

Niëns LM, Cameron A, van de Poel E, Ewen M, Laing R, Brouwer WBF. Practical measurement of affordability: an application to medicines. Bulletin of the World Health organization 2012; 90(2): 219-227.

Palangila RF, van den Bos GAM, Stam HJ, van Exel NJA, Brouwer WBF, Roebroeck ME. Subjective caregiver burden in parents of adults with Duchenne muscular dystrophy. A cross-sectional study. Disability and Rehabilitation 2012; 34(12):988-996.

van de Poel E, van Doorslaer E, O’Donnell O. Measurement of inequity in health care with heterogeneous response of use to need. Journal of Health Economics 31 2012; (31):676-689.

van de Poel E, O’Donnell O, Van Doorslaer E. Is there a health penalty of China’s rapid urbanization? Health Economics  2012; (21):367-385.

Poleij MJ, Brouwer WBF, van Exel NJA, Tibboel D. Assessing Health-Related Quality of Life Changes in Informal Caregivers: An Evaluation in Parents of Children with Major Congenital Anomalies. Quality of Life Research 2012;21(5):849-861.

Rappange DB, Brouwer WBF. The evaluation of lifestyle interventions in the Netherlands. Health Economics, Policy & Law 2012; 7(2):243-261.

Rutten-van Mölken MPMH, Goossens LMA. Cost Effectiveness of Pharmacological Maintenance Treatment for Chronic Obstructive Pulmonary Disease. A Review of the Evidence and Methodological Issues.Pharmacoeconomics 2012; 30 (4):1-32.

Tan SS, Bouwmans-Frijters CAM, Hakkart-van Roijen L. Handleiding voor kostenonderzoek: methode en referentieprijzen voor economische evalaties in de gezondheidszorg. Tijdschrift voor gezondheidswetenschappen 2012; 90(6):367-372.

Tan SS, Bakker J, Hoogendoorn ME, Kapila A, Martin J, Pezzi A, Pittoni G, Spronk PE, Welte R, Hakkaart-van Roijen L. Direct Cost Analysis of Intensive Care Unit Stay in Four European Countries: Applying a Standardized Costing Methodology. Value in Health 2012; (15):81-86.

Tan SS, Bouwmans CAM, Rutten FFH, Hakkaart-van Roijen L. Update of the Dutch Manual for Costing in Economic Evaluations. International Journal of Technology Assessment in Health Care 2012; (28)2:152–158.

Tan SS, Hakkaart-van Roijen L, van Ineveld BM, Redekop WK. Explaining length of stay variation of episodes of care in the Netherlands. The European Journal of Health Economics (2012).Oktober 2012.

Tilford JM, Payakachat N, Kovacs E, Pyne JM, Brouwer WBF, Nick T, Bellado J, Kuhlthau K. Preference-based health-related quality of life outcomes in children with autism spectrum disorders: a comparison of generic instruments. PharmacoEconomics 2012; 30(8): 661-679.

Tilling C, Krol M, Brazier J, Tsuchia A, van Exel NJA, Brouwer WBF. Does the EQ-5D reflect lost earnings?PharmacoEconomics 2012; 30(1): 47-61.

Verhoef TI, Redekop WK, van Schie RM, Bayat S, Daly AK, Geitona M, Haschke-Becher E, Hughes DA, Kamali F, Levin LA, Manolopoulos VG, Pirmohamed M, Siebert U, Stingl JC, Wadelius M, de Boer A, Maitland-van der Zee AH; The EU-PACT group. Cost-effectiveness of pharmagenetics in anticoagulation: international differences in health care systems and costs. Pharmacogenomics. 2012 Sep;13(12):1405-1417.

Versteegh MM, Leunis A, Luime JJ, Boggild M, Uyl-de Groot CA, Stolk EA. Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D. Med Decis Making 2012; (32):554-568.

Westra TA, Parouty M, Brouwer WBF, Rogoza RM, Rozenbaum MH, Daemen T, Wilschut JC, Boersma C Postma MJ. On discounting of health gains from human papillomavirus vaccination: Effects of different approaches. Value in Health 2012; 15(3): 562-567.

Zelle SG, Nyarko KM, Bosu WK, Aikins M, Niens LM, Lauer JA, Sepulveda CR, Hontelez JAC, Baltussen R. Costs, effects and cost-effectiveness of breast cancer control in Ghana. Tropical Medicine and International Health, Volume 17 no 8 pp 1031-1043 August 2012.

Zhang W, Bansback N, Boonen A, Severens JL, Anis AH. Development of a Composite Questionnaire, the Valuation of Lost Productivity, to Value Productivity Losses: Application in Rheumatoid Arthritis. Value in Health 2012; (15):46–54.